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RelapseAbstract In this study, we proposed an entropic analysis to overcome limitations of conventional
statistical methods to analyze clinical data for cancer patients who experienced relapse of tumors
following chemotherapy. We have applied this entropic method to reveal potential mechanisms that
lead to a relapse of Wilms’ tumor in pediatric patients. Results indicate b-tubulin isotype III up-
regulation is likely the primary cause of the relapse.
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Relapse of tumors has been a major clinical challenge after
patients received treatments either involving surgical removal,
radiotherapy or chemotherapy (Boisgerault et al., 2013).
Researchers and clinical practitioners have attempted to corre-
late clinical results and potential risk factors to identify molec-
ular mechanisms of relapse including EGF-like growth factor
over-expression (Tagliabue et al., 2003) in breast cancer and
up-regulation of several genes (e.g. CLDN16 and TJP3) in
ovarian cancer (Laios et al., 2008). Besides biological factors,
healthcare providers have reported that a common question
from patients is whether stress factors may be playing a role
in triggering the relapse of tumors. However, some studiesdid not ﬁnd any relationship between stress response and can-
cer relapse (Todd et al., 2014).
Therefore, many attempts have been subsequently focused
on determining biological mechanisms of relapse at a molecu-
lar level aimed at eventually developing improved treatments.
For example, an integrative model for relapse in ovarian can-
cer was developed to identify genes that can be related to the
relapse and can become the target for better therapy aimed
at decreasing drug resistance and optimizing the efﬁcacy of
existing drugs (Laios et al., 2008).
Our goal is to develop an information-driven approach in
order to interpret clinical data based on the available informa-
tion relevant to binding properties of drugs and biological tar-
gets. Results of this approach may reveal deeper insights into
mechanisms of the relapse of cancer after patients receive
chemotherapy. We hope this will unveil new directions in the
redesign of drugs to overcome cancer recurrence.
The foundation of the proposed approach is based on
information theory. Information theory has been shown to
be an appropriate and robust method to make inference from
insufﬁcient data to resolve problems in complex systems
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numerous applications) with the least bias (Tseng and
Tuszynski, 2014). Particularly, the method of maximum
entropy (ME) has been proved to be a powerful tool for induc-
tive inference to objectively process information (Gifﬁn et al.,
2007; Caticha et al., 2007). Tseng and Tuszynski further
reviewed and demonstrated that drug discovery can substan-
tially beneﬁt from the method of ME (Tseng and Tuszynski,
2014). Therefore, based on this method, we proposed an entro-
pic analysis approach. Since the method of ME is a universal
inductive inference tool (Gifﬁn et al., 2007; Caticha et al.,
2007), the proposed method can be applied to study the relapse
of different types of tumors as long as information used is rel-
evant to the problem of interests.
To demonstrate the use of the entropic analysis approach,
we consider a case study, which was designed to uncover pos-
sible mechanisms of the relapse of Wilms’ tumor in pediatric
oncology patients. As has been already shown through metas-
tudies, although the treatment protocols developed either by
the National Wilms’ Tumor Study Group (NWTSG) or the
International Society of Pediatric Oncology (SIOP) over the
years have an increased patient survival rate, there is still
approximately 15% of WT patients who developed relapse
of the disease (Geller and Dome, 2010). Therefore, one clinical
challenge in treating Wilms’ tumor is to investigate mecha-
nisms of the relapse of Wilms’ tumor in patients who received
tubulin-target based chemotherapy including the drug vin-
cristine. Speciﬁcally, the meta-study conducted by Grundy in
the Pediatric Oncology Group at the Cross Cancer Institute,
Edmonton, was aimed to determine whether variations in the
tubulin isotype expression may be responsible for drug resis-
tance and correlate these ﬁndings with two stages of relapse
(early and late).
Fig. 1 shows the mean expression levels of 13 samples (sam-
ple ID and six b-tubulin isotype types are listed in Table 1) from
78 measurements in this case study (Grundy). Fig. 2 shows theFigure 1 Histogram of mean expression level of b-tubulin
isotypes, the gene names are recorded in the x-axis, for the
treated patients who are at three stages of relapse of Wilms’
tumor. Note that the label inside parentheses is the short
annotation for probe sets used in the studies. The original
annotations are shown in ﬁrst column in Table 1.detailed distribution of all expression levels in each sample. It
includes 56 cases where there is no relapse of tumor after
tubulin-target chemotherapy treatments, 10 cases are found
to have early relapse and 12 cases show late relapse. As shown
in Fig. 1, it appears that there are no signiﬁcant differences in
the mean expression values among the different stages of
relapse of tumors for each tubulin isotype in each sample.
Yet the differences in the expression level distribution for each
tubulin isotype in each sample in Fig. 2 seem to disagree with
the results from the mean values. Since there are no signiﬁcant
differences in the mean values, we can expect that commonly
used statistical hypothesis tests are unlikely to provide mean-
ingful insights. The question that arises is whether we can make
any inferences based on the histograms in Fig. 2 to gain insights
into the role of b-tubulin isotypes in the relapse of tumors. This
question is exactly the problem that the method of ME is
designed to answer based on insufﬁcient data.
According to the proposed entropic analysis, we showed
that the late relapse is primarily associated with b-tubulin
isotype III expression levels. Namely, b-tubulin isotype III
over-expression is likely to be the key reason for drug resis-
tance. This result combined with the conclusions by Tseng
et al. (2010), which indicate b-tubulin isotype III as the most
important molecular target to inhibit microtubule polymeriza-
tion and eliminate cancer cells, suggests a potential combina-
tion chemotherapy, which targets not only b-tubulin isotype
III but also its possible mutations.
2. Methods and materials
2.1. Entropic analysis
The proposed approach is based on the method of ME. The
foundation of the method of ME hinges on the Bayesian inter-
pretation of probability and the rules of probability theory.
The former treats probability as a measure of our state of
knowledge about the system of interest rather than a frequency
of occurrence of an event. The latter demonstrates that this
type of probability can be manipulated by the rules of subtrac-
tion, multiplication and addition given by the standard proba-
bility theory (Gifﬁn et al., 2007; Caticha et al., 2007). These
two tools form the building blocks for inductive inference
and its core is the concept of entropy. The most important fac-
tor in applying this scheme to solve speciﬁc problems is to ask
‘‘the right question’’. Afterward, the principle of ME indicates
the most preferable inference one can make to answer that
question is the one that maximizes entropy of the problem of
interests. Furthermore, the method of ME indicates that given
two probability distributions of a system at a speciﬁc state i,
P1ðiÞ and P2ðiÞ, the relative entropy of these two probability
distributions:
SðP1;P2Þ ¼ 
X
i
P1ðiÞ logP1ðiÞ
P2ðiÞ 6 0; ð1Þ
is shown to quantify the difference between these two proba-
bility distributions. Furthermore, when P2ðiÞ is set to a refer-
ence distribution (for example, it can be a uniform
distribution to represent our complete ignorance of the system
of interest), one can utilize this relative entropy to represent a
preference scale to rank possible probability distributions of
the system (Tseng, 2006; Chen et al., 2007).
Table 1 Results of entropic analysis on investigating the relapse of Wilms’ tumor.
Gene name Sample ID (UG133 Probe set ID) SðPearly;PnonÞ P0ðXearlyÞdX SðPlate;PnonÞ P0ðXlateÞdX
TUBB 209026_x_at 0.025 0.024 114.86 1
211714_x_at 0.293 0.254 0.194 0.177
212320_at 0.089 0.085 0.117 0.111
TUBB1 208601_s_at 0.506 0.397 0.128 0.12
TUBB2 204141_at 0.471 0.376 0.298 0.257
208977_x_at 0.197 0.179 57.454 1
213726_x_at 0.419 0.342 57.677 1
209372_x_at 0.258 0.227 0.457 0.367
TUBB3 202154_x_at 0.075 0.072 57.503 1
213476_x_at 0.362 0.303 57.525 1
TUBB4 212664_at 0.151 0.14 0.164 0.152
TUBB4Q 211915_s_at 0.057 0.055 0.039 0.322
TUBB6 209191_at 0.221 0.198 0.289 0.251
Relative entropy SðP1;P2Þ was calculated from Eq. (1).
Probability P0ðX1ÞdX was calculated from Eq. (3).
Figure 2 Comparisons of histograms of normalized occurrences of speciﬁc expression levels of b-tubulin isotypes from the treated
patients at three stages of relapse of Wilms’ tumor.
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here, we then consider ‘‘what is the probability that the expres-
sion levels of biological targets of chemotherapy in tumor-relapse
patients differ from the ones in normal conditions’’ as ‘‘the right
question’’ to ask. Speciﬁcally, we want to focus on b-tubulin
based chemotherapy and quantify whether the tubulin isotype
expression levels represent mechanisms to cause relapse of
tumors. Since there are many factors inﬂuencing the measure-
ment of b-tubulin isotypes expression levels (Leandro-Garcı´a
et al., 2010), the concept of probability distribution to compre-
hend these kinds of uncertainty is an appropriate usage of the
ME method. Namely, we are interested in determining the
differences between the probability distributions of b-tubulin
isotype expressions when cells are subjected to different condi-
tions (for example, patients with no relapse vs early stage of
relapse). The degree of these differences then provides essential
information to indicate the inﬂuence of speciﬁc b-tubulin
isotype expression levels on potential causes of tumor relapse.
Furthermore, we considered the expression level of a speciﬁc
b-tubulin isotype to represent the human body at a speciﬁc
state, which can be the patient who received chemotherapy
and had either no, early or late relapse afterward. Next, we sim-
ply utilize the normalized histogram of expression levels for
each tubulin isotype obtained from patient data at this stage
to deﬁne the probability of a tubulin isotype having expression
level i, XðiÞ, given the patient who has either early or late
relapse, P1ðiÞ. The bin size for appropriately sampling expres-
sion level data for each sample is chosen to be within the corre-
sponding standard deviation. Next, for the purpose of
investigating the mechanisms of relapse in the framework of
ME, we considered the probability distribution of a tubulin iso-
type having expression level i given the patient who has no
relapse as the reference distribution P2ðiÞ: The mean reference
expression level is given by X ¼PiP2ðiÞXðiÞ. For patients
who had relapse, the mean expression level is given by
X0 ¼PiP1ðiÞXðiÞ assuming that X0 ¼ Xþ dX. Therefore, the
relative entropy, Eq. (1), of probability distributions for speciﬁc
tubulin isotype expression levels in patients who had relapse
and no relapse allows us to quantify their differences. The larger
the difference, the higher the chances that the corresponding
tubulin isotype is likely responsible for the different stages of
relapse. Note that the relative entropy measure provides a scale
to quantify the differences between two distributions. However,
the statistical signiﬁcance of these differences is still unclear.
Therefore, we proposed to apply the Einstein ﬂuctuation
theory to resolve this issue (Caticha et al., 2007; Callen
et al., 1985). Based on the ﬂuctuation theory, one can show
that the given relative entropy of two distributions, Eq. (1),
can determine the probability of observing X0 to deviate from
reference X by dX, which is given by:
PðX0ÞdX ¼ expSðP1;P2Þ: ð2Þ
On the other hand, within the difference dX, PðX0ÞdX rep-
resents the probability of P1ðiÞ being identical to P2ðiÞ.
Therefore, we can deﬁne the probability of P1ðiÞ being differ-
ent from P2ðiÞ by:
P0ðX0ÞdX ¼ 1 expSðP1;P2Þ: ð3Þ
Namely, this probability indicates that the chances of either
early or late relapse (represented by P1ðiÞ) being different from
no relapse (P2ðiÞ) is under consideration of a speciﬁc tubulin
isotype. This will then be the indicator used in the case studyto determine whether differences between tubulin isotype
expression levels are critical factors that affect the probability
of relapse.
2.2. Case study: Wilms’ tumor
This case study was designed following our earlier work (Tseng
et al., 2010; Huzil et al., 2007) on drug resistance using
b-tubulin, a major component of microtubules, as a model.
According to this earlier work (Tseng et al., 2010; Huzil
et al., 2007), binding sites for taxol-based and vinca alkaloids
in b-tubulin have been identiﬁed and are considered as hot
spots for mutations that hamper therapeutic effects of those
drugs. Moreover, each tubulin isotype has a different afﬁnity
for various chemotherapy agents and this can be used as a
strategy to mitigate the effects of chemotherapy drugs by
tumor cells (Huzil et al., 2006). Therefore, the goal of this
study is to quantify tubulin expression levels and potentially
screen for mutations in the b-tubulin gene, speciﬁcally in those
locations which correspond to the binding sites for the
chemotherapy drugs acting on tubulin in the cells of Wilms’
tumors. The present study aimed to answer the following
two questions. First, what is the level of b tubulin isotype
expression in patients whose disease recurs and second, what
is the probability that a difference in the expression levels of
tubulin isotypes exist between those who relapse and those
who do not. A future study should also investigate similar
questions directed at speciﬁc somatic single point mutations
in tubulin genes.
Table 1 lists 14 UG133 probe sets from Affymetrix Inc.
used to explore the interactions of six b-tubulin isotypes and
vinca alkaloids. The ﬁrst column records the name of b-
tubulin isotype gene (HUGO ID) and the second column
denotes probe set ID. Sequences bearing the predicted muta-
tions (S172A, P173A, D197N, K350N) will be exclusively tar-
geted for sequencing.
Note that the data received (Grundy) refer to the expression
levels of b-tubulin rather than the mutation rate. The latter
should be investigated by an additional study. Also note that
for some genes such as TUBB, there are three samples while
some others have only one sample. This is due to a varying
level of sample quality.
3. Results and discussion
We conclude the following based on the data analysis per-
formed: (1) b-tubulin isotype III (gene name is TUBB3)
expression plays the major role and (2) b-tubulin isotype II
(TUBB2) expression as the secondary factor in causing late
relapse of tumor. Fig. 2 plots the normalized histogram of
expression levels of each tubulin isotype in each sample at
three stages of relapse. By deﬁning the probability distribution
for speciﬁc tubulin isotype expression levels in each sample at
early and late stages of relapse and no relapse based on these
histograms, the relative entropy of the probability distribu-
tions for either early or late relapse and no relapse, the results
of Eq. (1) are calculated and shown in the third and ﬁfth col-
umns in Table 1, respectively. Thereafter, one can calculate the
probabilities of either early P0 Xearly
 
dX or late P0 Xlateð ÞdX
relapse being different from no relapse under consideration
of a speciﬁc tubulin isotype, Eq. (3), as shown in the fourth
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bility distributions are shown to have large ﬂuctuations except
the one for TUBB3 in the late relapse case, whose expression
level distributions in both samples are at 100% probability dif-
ferent from the distributions of no relapse. Furthermore, the
inconsistency between the P0 Xearly
 
dX and P0ðXlateÞdX results
suggests that the corresponding tubulin isotypes do not have
strong correlations with the cause and the stage of relapse.
TUBB3 among all isotypes likely plays a major role in trigger-
ing late relapse of tumor. Furthermore, since there are two out
of four samples (208977_x_at and 213726_x_at) in TUBB2, we
also have P0ðXlateÞdX ¼ 1, and we may infer that TUBB2 may
play a secondary role in late relapse.
As mentioned previously, because P0ðXearlyÞdX shows large
ﬂuctuations for all tubulin isotypes, it is difﬁcult to conclude
that the tubulin isotype expression level distributions for sam-
ples with early relapse are different from the one with no
relapse. Therefore, this indicates that all b-tubulin isotypes
mutations are unlikely to correlate with causes of the early
stage of relapse.
4. Summary
In this paper, we have proposed an approach based on entro-
pic inductive inference to interpret clinical results for pediatric
oncology patients with Wilms’ tumor who received chemother-
apy utilizing information regarding the molecular target (tubu-
lin isotypes) expression levels relevant for the chemotherapy
drugs used. This approach reveals probabilities of biological
targets responsible for the relapse of cancers after patients
received chemotherapy. We have applied the maximum
entropy method to investigate the relapse of Wilms’ tumor
as only one example. Our studies indicate that b-tubulin iso-
type III plays a relatively more important role than other iso-
types and shows resistance to vinca-based chemotherapy in
late stages of treatments and it is correlated with the causes
for tumor recurrence. It further suggests that an effective treat-
ment plan to prevent the recurrence should include either mod-
iﬁed vinca-based drugs or alternatives that can bind to tubulin
isotype III with a high afﬁnity. A method of optimizing drug
selection for speciﬁc tubulin expression proﬁles in both tumor
cells and healthy tissues has been recently published
(Ravanbakhsh et al., 2013) and it can be used in future work
on rational drug design for Wilms’ tumor and other neoplastic
diseases with tubulin as a therapeutic target.
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